Evaluation of Repeated Whole Brain Radiotherapy Versus Best Supportive Care for Multiple Brain Metastases.

Launched by STEPHANIE COMBS · Sep 16, 2017

Keywords

ClinConnect Summary

According to Nussbaum et al., 24-45% of cancer patients develop cerebral metastases during the course of the disease. Brain metastases are generally associated with a poor prognosis and high morbidity. Published median survival rates after WBRT are between 2 and 7 months. Standard of care in multiple BM is WBRT delivered as 30 Gy in 10 fractions, leading to modest palliation with a median survival of 3 to 5 months. Prognostic factors include the RPA-classification, performance status, response to steroids and evidence of systemic disease.

Unfortunately, intracerebral recurrence happens. Fo...

Gender

ALL

Eligibility criteria

• Inclusion criteria:
• • histologically confirmed malignancy
• • previous WBRT
• • MR-imaging confirmed cerebral metastases (\>1)
• • age ≥ 18 years of age
• • Karnofsky Performance Score ³60
• • For women with childbearing potential, (and men) adequate contraception.
• • Ability of subject to understand character and individual consequences of the clinical trial
• • Written informed consent (must be available before enrolment in the trial)
• • Exclusion Criteria
• • refusal of the patients to take part in the study
• • Patients who have not yet recovered from acute high-grade toxicities of prior therapies
• • Pregnant or lactating women
• • Participation in another clinical study or observation period of competing trials, respectively